ACLX
Arcellx, Inc. NASDAQ Listed Feb 4, 2022$115.07
Mkt Cap $6.7B
52w Low $47.86
99.9% of range
52w High $115.13
50d MA $110.81
200d MA $83.72
P/E (TTM)
-28.3x
EV/EBITDA
-18.6x
P/B
16.1x
Debt/Equity
0.2x
ROE
-56.9%
P/FCF
-17.3x
RSI (14)
—
ATR (14)
—
Beta
0.25
50d MA
$110.81
200d MA
$83.72
Avg Volume
2.4M
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
25 West Watkins Mill Road · Redwood City, MD 20878 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -1.01 | -1.01 | +0.0% | 113.88 | +0.1% | -0.1% | +0.1% | +0.1% | +0.4% | +0.4% | — |
| Nov 5, 2025 | AMC | -0.96 | -0.99 | -3.1% | 87.51 | -0.0% | +0.8% | -1.1% | -2.1% | +3.1% | +3.0% | — |
| Aug 7, 2025 | AMC | -1.03 | -0.94 | +8.7% | 71.15 | -0.6% | -0.9% | -2.9% | +1.9% | -0.2% | +1.0% | — |
| May 8, 2025 | AMC | -0.84 | -1.13 | -34.5% | 56.26 | -0.3% | +2.3% | +5.8% | +3.5% | +4.9% | +3.9% | — |
| Feb 27, 2025 | AMC | -0.63 | -0.87 | -38.1% | 61.39 | -4.4% | +5.6% | +2.0% | +6.9% | +12.2% | +11.7% | — |
| Nov 7, 2024 | AMC | -0.54 | -0.48 | +11.1% | 99.16 | +0.8% | +3.9% | +7.4% | +1.3% | +1.0% | -4.1% | — |
| Aug 8, 2024 | AMC | -0.54 | -0.51 | +5.6% | 52.58 | +2.1% | +12.3% | +12.1% | +15.3% | +14.6% | +23.4% | — |
| May 9, 2024 | AMC | -0.51 | -0.14 | +72.5% | 52.73 | -1.7% | -5.7% | -5.6% | -4.0% | -1.9% | +0.1% | — |
| Feb 28, 2024 | AMC | -0.61 | 0.42 | +168.9% | 67.32 | +3.1% | -2.2% | -0.7% | +0.9% | +3.4% | +8.4% | — |
| Nov 13, 2023 | AMC | -0.56 | -0.81 | -44.6% | 45.50 | +1.1% | +4.3% | +9.9% | +14.7% | +21.3% | +15.6% | — |
| Aug 14, 2023 | AMC | -0.68 | -0.50 | +26.5% | 33.68 | +11.7% | +6.6% | +5.6% | +3.6% | +3.3% | +4.3% | — |
| May 8, 2023 | AMC | 2.52 | -0.58 | -123.0% | 43.23 | +1.0% | +3.7% | +8.5% | +3.1% | -3.8% | +0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26 | Guggenheim | Downgrade | Buy → Neutral | — | $113.76 | $113.80 | +0.0% | +0.1% | +0.0% | +0.3% | +0.3% | +0.5% |
| Feb 24 | Citigroup | Downgrade | Buy → Neutral | — | $113.75 | $113.78 | +0.0% | +0.0% | +0.0% | +0.1% | +0.0% | +0.3% |
| Feb 24 | Stifel | Downgrade | Buy → Hold | — | $113.75 | $113.78 | +0.0% | +0.0% | +0.0% | +0.1% | +0.0% | +0.3% |
| Feb 24 | Evercore ISI | Downgrade | Outperform → In Line | — | $113.75 | $113.78 | +0.0% | +0.0% | +0.0% | +0.1% | +0.0% | +0.3% |
| Feb 24 | Truist | Downgrade | Buy → Hold | — | $113.75 | $113.78 | +0.0% | +0.0% | +0.0% | +0.1% | +0.0% | +0.3% |
| Feb 24 | UBS | Downgrade | Buy → Neutral | — | $113.75 | $113.78 | +0.0% | +0.0% | +0.0% | +0.1% | +0.0% | +0.3% |
| Feb 24 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $113.75 | $113.78 | +0.0% | +0.0% | +0.0% | +0.1% | +0.0% | +0.3% |
| Feb 23 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $64.11 | $114.14 | +78.0% | +77.4% | +77.4% | +77.4% | +77.6% | +77.5% |
| Feb 23 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $64.11 | $114.14 | +78.0% | +77.4% | +77.4% | +77.4% | +77.6% | +77.5% |
| Feb 23 | Baird | Downgrade | Outperform → Neutral | — | $64.11 | $114.14 | +78.0% | +77.4% | +77.4% | +77.4% | +77.6% | +77.5% |
| Feb 23 | Needham | Downgrade | Buy → Hold | — | $64.11 | $114.14 | +78.0% | +77.4% | +77.4% | +77.4% | +77.6% | +77.5% |
| Feb 5 | Needham | Maintains | Buy → Buy | — | $69.38 | $70.02 | +0.9% | -3.5% | -1.9% | -0.8% | -3.1% | +0.7% |
| Feb 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.46 | $70.14 | +1.0% | -0.1% | -3.6% | -2.1% | -1.0% | -3.2% |
| Dec 8 | Needham | Maintains | Buy → Buy | — | $69.56 | $74.95 | +7.7% | +6.5% | +1.8% | +3.5% | +4.5% | +3.3% |
| Dec 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $69.56 | $74.95 | +7.7% | +6.5% | +1.8% | +3.5% | +4.5% | +3.3% |
| Nov 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $90.25 | $89.84 | -0.5% | -4.6% | -2.3% | -3.0% | -2.3% | -4.1% |
| Jul 31 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $71.54 | $71.60 | +0.1% | -0.2% | -0.6% | +0.8% | +0.7% | -1.2% |
| Jun 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $66.00 | $66.73 | +1.1% | -2.9% | -4.7% | -3.3% | -4.5% | -3.6% |
| May 9 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $56.26 | $56.07 | -0.3% | +2.3% | +5.8% | +3.5% | +4.9% | +3.9% |
| Dec 10 | Needham | Maintains | Buy → Buy | — | $82.95 | $84.14 | +1.4% | -0.8% | +4.9% | +0.6% | +1.0% | +0.6% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $82.95 | $84.14 | +1.4% | -0.8% | +4.9% | +0.6% | +1.0% | +0.6% |
| Dec 10 | UBS | Maintains | Buy → Buy | — | $82.95 | $84.14 | +1.4% | -0.8% | +4.9% | +0.6% | +1.0% | +0.6% |
| Dec 9 | Needham | Maintains | Buy → Buy | — | $84.55 | $88.75 | +5.0% | -1.9% | -2.7% | +2.9% | -1.3% | -0.9% |
| Nov 12 | Truist | Maintains | Buy → Buy | — | $106.53 | $106.33 | -0.2% | -5.7% | -6.0% | -10.7% | -17.6% | -17.2% |
| Nov 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $99.16 | $99.94 | +0.8% | +3.9% | +7.4% | +1.3% | +1.0% | -4.1% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $99.16 | $99.94 | +0.8% | +3.9% | +7.4% | +1.3% | +1.0% | -4.1% |
| Nov 8 | Needham | Maintains | Buy → Buy | — | $99.16 | $99.94 | +0.8% | +3.9% | +7.4% | +1.3% | +1.0% | -4.1% |
| Nov 6 | BofA Securities | Maintains | Buy → Buy | — | $87.12 | $94.34 | +8.3% | +6.7% | +13.8% | +18.3% | +22.3% | +15.3% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $87.12 | $94.34 | +8.3% | +6.7% | +13.8% | +18.3% | +22.3% | +15.3% |
| Nov 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $87.12 | $94.34 | +8.3% | +6.7% | +13.8% | +18.3% | +22.3% | +15.3% |
| Nov 6 | Needham | Maintains | Buy → Buy | — | $87.12 | $94.34 | +8.3% | +6.7% | +13.8% | +18.3% | +22.3% | +15.3% |
| Nov 6 | Baird | Maintains | Outperform → Outperform | — | $87.12 | $94.34 | +8.3% | +6.7% | +13.8% | +18.3% | +22.3% | +15.3% |
| Oct 31 | Needham | Maintains | Buy → Buy | — | $86.81 | $86.42 | -0.4% | -2.9% | -0.7% | -0.4% | +0.4% | +7.1% |
| Oct 22 | Needham | Maintains | Buy → Buy | — | $90.28 | $89.69 | -0.7% | +0.2% | -2.3% | -4.2% | -6.6% | -5.9% |
| Oct 18 | Stifel | Maintains | Buy → Buy | — | $95.27 | $95.90 | +0.7% | +1.7% | -5.2% | -5.0% | -7.4% | -9.2% |
| Oct 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $93.00 | $94.70 | +1.8% | +2.4% | +4.2% | -2.9% | -2.7% | -5.2% |
| Aug 9 | Needham | Maintains | Buy → Buy | — | $52.58 | $53.70 | +2.1% | +12.3% | +12.1% | +15.3% | +14.6% | +23.4% |
| Jul 22 | Canaccord Genuity | Maintains | Buy → Buy | — | $62.56 | $63.11 | +0.9% | +0.7% | +1.0% | -0.7% | +0.2% | +3.0% |
| Jun 18 | Truist | Maintains | Buy → Buy | — | $53.75 | $53.90 | +0.3% | +0.1% | +1.6% | +4.4% | +4.3% | +0.1% |
| May 15 | Stifel | Maintains | Buy → Buy | — | $50.62 | $52.26 | +3.2% | +2.2% | +4.3% | +5.9% | +7.4% | +5.2% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.74 | $50.44 | +1.4% | +0.1% | +1.8% | +4.0% | +6.1% | +7.8% |
| May 10 | Needham | Maintains | Buy → Buy | — | $52.73 | $51.81 | -1.7% | -5.7% | -5.6% | -4.0% | -1.9% | +0.1% |
| May 7 | Needham | Maintains | Buy → Buy | — | $52.67 | $52.78 | +0.2% | -0.5% | -0.8% | +0.1% | -5.6% | -5.5% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $59.08 | $59.54 | +0.8% | +1.8% | -1.7% | -3.6% | -6.5% | -9.4% |
| Mar 18 | Needham | Maintains | Buy → Buy | — | $70.62 | $70.96 | +0.5% | -2.1% | +3.4% | +4.1% | +2.0% | -0.6% |
| Mar 14 | Stifel | Maintains | Buy → Buy | — | $70.55 | $70.17 | -0.5% | -1.4% | +0.1% | -2.0% | +3.5% | +4.2% |
| Mar 5 | Truist | Maintains | Buy → Buy | — | $67.91 | $67.64 | -0.4% | +2.5% | +7.4% | +4.2% | +6.5% | +1.4% |
| Feb 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.32 | $69.40 | +3.1% | -2.2% | -0.7% | +0.9% | +3.4% | +8.4% |
| Feb 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $67.32 | $69.40 | +3.1% | -2.2% | -0.7% | +0.9% | +3.4% | +8.4% |
| Feb 29 | Baird | Maintains | Outperform → Outperform | — | $67.32 | $69.40 | +3.1% | -2.2% | -0.7% | +0.9% | +3.4% | +8.4% |
No insider trades available.
SC TO-T/A
! Medium
Arcellx, Inc. -- Tender Offer Amendment
Gilead Sciences is acquiring Arcellx at $115 per share through a tender offer, providing ACLX shareholders a defined exit while consolidating GILD's cell therapy portfolio.
Apr 28
SC TO-T/A
! Medium
Arcellx, Inc. -- Tender Offer Amendment
Gilead Sciences' tender offer to acquire Arcellx at $115 per share represents a significant premium and provides shareholders with a clear exit opportunity at a fixed price through April 2026.
Apr 17
SC TO-T/A
! Medium
Arcellx, Inc. -- Tender Offer Amendment
Gilead Sciences is acquiring Arcellx at $115 per share in cash, valuing the cell therapy company at approximately $2.1 billion.
Apr 1
SC TO-T
!!! Very High
Arcellx, Inc. -- Tender Offer
Gilead Sciences is acquiring Arcellx for $115 per share in cash, representing a significant premium that validates Arcellx's cell therapy platform and expands Gilead's oncology portfolio.
Mar 6
8-K
Arcellx, Inc. -- 8-K Filing
Gilead Sciences' cash acquisition of Arcellx remains on track with no financing risk, as the offer period opens for at least 20 business days with potential extension under merger terms.
Feb 23
Data updated apr 24, 2026 10:36am
· Source: massive.com